Clinical applications of pharmacogenomics guided warfarin dosing.

about

Giving and withholding of information following genomic screening: challenges identified in a study of primary care physicians in Estonia.

P2860

Q50986179-15BEBEB7-3D44-4F07-89AE-73C5A67BC9E5

P2860

Clinical applications of pharmacogenomics guided warfarin dosing.

Item

http://www.wikidata.org/entity/Q37807280

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Clinical applications of pharmacogenomics guided warfarin dosing.

@en

Clinical applications of pharmacogenomics guided warfarin dosing.

@nl

type

Item

label

Clinical applications of pharmacogenomics guided warfarin dosing.

@en

Clinical applications of pharmacogenomics guided warfarin dosing.

@nl

prefLabel

Clinical applications of pharmacogenomics guided warfarin dosing.

@en

Clinical applications of pharmacogenomics guided warfarin dosing.

@nl

P1476

Clinical applications of pharmacogenomics guided warfarin dosing.

@en

P2093

Geoffrey C Wall

http://www.w3.org/2001/XMLSchema#string

Heidi J Price

http://www.w3.org/2001/XMLSchema#string

Kristin S Meyer

http://www.w3.org/2001/XMLSchema#string

Pramod Mahajan

http://www.w3.org/2001/XMLSchema#string

P2860

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

Estimation of the warfarin dose with clinical and pharmacogenetic data.

Integration of genetic, clinical, and INR data to refine warfarin dosing.

Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.

Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.

Genetic determinants of response to warfarin during initial anticoagulation

Evaluation of genetic factors for warfarin dose prediction

Are genetic self-tests dangerous? Assessing the commercialization of genetic testing in terms of personal autonomy.

P2888

s11096-010-9448-z

P304

359-368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11096-010-9448-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21052837

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

Clinical applications of pharmacogenomics guided warfarin dosing.

about

P2860

P2860

Clinical applications of pharmacogenomics guided warfarin dosing.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921